Esbriet
utilized to manage idiopathic pulmonary fibrosis to alleviate lung fibrosis progression.
Strengths: 200 · 400mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Antifibrotic agent
- Pharmacological class
Pyridine carboxylic acid derivative
- Minor side effects
nausea; rash; fatigue; diarrhoea; dyspepsia; abdominal pain
- Moderate side effects
photosensitivity reaction; pruritus; dizziness; headache; decreased appetite
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Roche
- Onset Time
2–4 weeks
- Duration
long-term
- Storage instructions
Store below 25°C, away from moisture and direct heat.
- Drug interactions
fluvoxamine; ciprofloxacin; tobacco
- Age restrictions
Not recommended for use in children or adolescents.
Contraindications
hypersensitivity to pirfenidone; severe hepatic impairment; severe renal impairment
Precautions and warnings
avoid sunlight and tanning lamps during treatment; monitor liver function regularly; photosensitivity reactions may occur
Serious side effects
elevated liver enzymes — requires immediate medical attention; angioedema — requires immediate medical attention
Patient summary
utilized to manage idiopathic pulmonary fibrosis to alleviate lung fibrosis progression.
Mechanism of action
Pirfenidone acts by modulating the production of growth factors and cytokines, reducing fibroblast proliferation and collagen synthesis in affected tissues, which helps slow the decline of lung function.
Pregnancy and breastfeeding
Pregnancy: Use is not recommended. Breastfeeding: Advised to discontinue breastfeeding during treatment.
Esbriet
utilized to manage idiopathic pulmonary fibrosis to alleviate lung fibrosis progression.
Editorial Notes
- Active ingredient(s): Pirfenidone
- Listed indication(s): Idiopathic Pulmonary Fibrosis
Usually available as
- 60 tablets - 200 mg1555-200-mg-18107
- 30 tablets - 400 mg1555-400-mg-18111